Safety and Efficacy of MK-5172 + MK-8742 in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052/C-SURFER)

Incluson criteria:

- Documented chronic (at least 6 months) HCV GT1 infection (with no evidence of mixed
genotypes or genotype that cannot be assigned a type)

- No evidence of cirrhosis (liver biopsy performed within 24 months of Day 1 of this
study showing absence of cirrhosis, or Fibroscan performed within 12 months of Day 1
of this study, or Fibrosure plus Aspartate Aminotransferase to Platelet Ratio Index
[APRI] obtained during the screening period)

- HCV treatment naive or HCV ribonucleic acid (RNA) treatment relapse after a pegylated
interferon-containing regimen

- Chronic kidney disease (defined as glomerular filtration rate [eGFR] <=29)
non-dialysis dependent or on hemodialysis for at least 3 months, including
individuals awaiting kidney transplant and those with failed kidney transplants but
no longer on immunosuppressant therapy)

- Female participant of reproductive potential must agree to remain abstinent or use
(or have their partner use) 2 acceptable methods of contraception from at least 2
weeks prior to Day 1 through 14 days after the last dose of study drugs, or longer if
dictated by local regulations

Exclusion criteria:

- Evidence of decompensated liver disease

- On peritoneal dialysis for management of kidney disease

- Co-infection with hepatitis B virus or human immunodeficiency virus (HIV)

- History of malignancy <=5 years prior to signing informed consent

- Clinical diagnosis of substance abuse

- Pregnant, breast-feeding, expecting to conceive or donate eggs, or donate sperm from
at least 2 weeks prior to Day 1 and until 14 days after the last study dose, or
longer if dictated by local regulations

- Organ transplant (including hematopoietic stem cell transplant) other than kidney,
cornea, and hair

- Conditions requiring, or likely to require, chronic systemic administration of
corticosteroids during the course of the trial

- Uncontrolled or poorly controlled hypertension

- Significant cardiovascular disorder (e.g. myocardial infarction or unstable angina)
or cardiovascular procedure within 3 months prior to signing informed consent

- New or worsening signs or symptoms of congestive heart failure within 3 months of
signing informed consent

- Severe active peripheral vascular disease

- Recent (within 3 months prior to signing informed consent) episode or recurrence of
stroke, transient ischemic attack (TIA) or neurological disorder, including but not
limited to seizures

- Evidence or history of chronic hepatitis not caused by HCV